Pharmaceuticals, Biotechnology and Life Sciences
Mallinckrodt will drop testing its Therakos in the Phase 3 clinical trial for treating young patients with Steroid Refractory Acute Graft-versus-Host Disease, after the interim results were published.
Faron Pharmaceuticals said Thursday in a press release that it is currently opening two UK sites (London, Birmingham) to expand the Matins trial, following recent CTA approval by the UK regulator, the Medicines & Healthcare products Regulatory Agency (MHRA).
Torque will test its Deep IL-15 Primed T Cells (TRQ-1501) with Merck, both as a single agent and in combination with Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in a Phase 1/2 study in multiple solid tumor indications.
Xencor has put on hold one of its studies on myeloid leukemia CD123 x CD3 bispecific antibody molecule XmAb14045, until the FDA lifts the hold, the company said Wednesday in a press release.
Alvogen has launched its generic equivalent to Indivior UK LLC’s Suboxone sublingual film (buprenorphine hydrochloride/naloxone hydrochloride) in the U.S.
Oncology drug specialist ADC Therapeutics has continued with its Phase I clinical trial of combination of ADCT-402 (loncastuximab tesirine) with Pharmacyclics LLC’s ibrutinib, by dosing patients with advanced diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL).
Beximco Pharmaceuticals Limited will buy from Novartis’ Sandoz a portfolio of eight Abbreviated New Drug Applications (ANDAs) in the US…
Pfizer and Eli Lilly have been testing tanezumab in patients with moderate-to-severe chronic low back pain (CLBP) in a Phase 3 study, with certain success, as tanezumab 10 mg met the primary endpoint by reducing pain at 16 weeks compared to placebo.
Roche on Tuesday got nod from the US Food and Drug Administration (FDA) that it’s anti-cancer combination might have the potential to provide significant improvements in the safety and effectiveness of the treatment, prevention or diagnosis of a serious disease.
Basilea Pharmaceutica’s revenue grew of 31% for the full year, reaching CHF 133 million (€117M), the company said on Tuesday, noting it’s year-end cash position being at CHF 223 million.